-
公开(公告)号：CA2500844A1
公开(公告)日：2004-04-15
申请号：CA2500844
申请日：2003-09-30
Applicant: CELLTECH R&D LTD
Inventor： DAVIS JEREMY MARTIN , LANGHAM BARRY JOHN , CUBBON RACHEL JANE , BROOKINGS DANIEL CHRISTOPHER
IPC: A61P19/00 , A61P29/00 , A61P37/00 , C07D471/04 , A61K31/437
Abstract: A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorde rs.
-
32.发明专利
公开(公告)号：SK18612001A3
公开(公告)日：2002-06-04
申请号：SK18612001
申请日：2000-06-19
Applicant: CELLTECH R&D LTD
Inventor： BATCHELOR MARK JAMES , MOFFAT DAVID FESTUS CHARLES , DAVIS JEREMY MARTIN , HUTCHINGS MARTIN CLIVE
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
-
公开(公告)号：BR0011770A
公开(公告)日：2002-03-05
申请号：BR0011770
申请日：2000-06-19
Applicant: CELLTECH R&D LTD
Inventor： BATCHELOR MARK JAMES , MOFFAT DAVID FESTUS CHARLES , DAVIS JEREMY MARTIN , HUTCHINGS MARTIN CLIVE
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
-
公开(公告)号：NO20016162L
公开(公告)日：2002-02-18
申请号：NO20016162
申请日：2001-12-17
Applicant: CELLTECH R&D LTD
Inventor： DAVIS JEREMY MARTIN , HUTCHINGS MARTIN CLIVE , BATCHELOR MARK JAMES , MOFFAT DAVID FESTUS CHARLES
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
-
公开(公告)号：BRPI0410653A
公开(公告)日：2006-07-04
申请号：BRPI0410653
申请日：2004-06-18
Applicant: CELLTECH R&D LTD
IPC: A61P29/00 , C07D495/04 , A61K31/4365
Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
-
Patent Agency Ranking
公开(公告)号：NZ537740A
公开(公告)日：2006-03-31
申请号：NZ53774003
申请日：2003-06-20
Applicant: CELLTECH R&D LTD
IPC: A61K31/4743 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/02 , A61P7/04 , A61P7/06 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P31/16 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D495/04 , A61K31/44
Abstract: Disclosed are compounds of the formula (I), wherein The dashed line joining A and C(Ra) is present and represents a bond, and A is a ûC(Rb)= group, or the dashed line is absent and A is a ûC(Rb)(Rc)- group; R is H or a straight or branched C1-6- alkyl group; X is an ûO- or ûS- atom; Y is a N or substituted C atom or a ûCH= group; N is 0 or 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain; L1 is a covalent bond or a linker atom or group; Cy1 is a H or an optionally a substituted cycloaliphatic, poly cycloaliphatic, hetereocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; And the salts, solvates, hydrates and N-oxides thereof. Further disclosed are pharmaceutical compositions comprising a compound of formula (I); and the use of one of the compounds of the invention for the manufacture of a medicament for the treatment of rheumatoid arthritis.
-
公开(公告)号：NO20041975L
公开(公告)日：2005-07-16
申请号：NO20041975
申请日：2004-05-13
Applicant: CELLTECH R&D LTD
IPC: A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/02 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04 , C07D495/04
Abstract: Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a -N- atom or a -N(R b )-, -C(R b )- or -C(R b )(R C )- group; R a , R b and R c is each independently a hydrogen atom or an optionally substituted C 1-6 alkyl group; X is an -O- or -S- atom or -NH- group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk 1 is an optionally substituted aliphatic or heteroaliphatic chain L 1 is a covalent bond or a linker atom or group; Cy 1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis
-
38.发明专利
公开(公告)号：ECSP055560A
公开(公告)日：2005-05-30
申请号：ECSP055560
申请日：2005-01-20
Applicant: CELLTECH R&D LTD
Inventor： BROOKINGS DANIEL CHRISTOPHER , DAVIS JEREMY MARTIN
IPC: A61K31/4743 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/02 , A61P7/04 , A61P7/06 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P31/16 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D495/04 , A61K31 , A61P29 , A61P37
Abstract: Se describen derivados heteroaromáticos bicíclicos de fórmula (1): donde:la línea discontinua que une a A y C(Ra) está presente y representa un enlace yA es un átomo -N= o un grupo -C(Rb)=, o la línea discontinua está ausente y A es un grupo -N(Rb)-, o -C(Rb)(Rc)-;X es un átomo de -O-, -S- o de nitrógeno sustituido o un grupo -S(O)-, -S(O2)- o -NH-;Y es un átomo de nitrógeno o de carbono sustituido o un grupo -CH=;n es cero o el número entero 1;Alk1 es una cadena alifática o heteroalifática opcionalmente sustituidaL1 es un enlace covalente o un átomo o grupo de unión;Cy1 es un átomo de hidrógeno o un grupo cicloalifático, policicloalifático, heterocicloalifático, poliheterocicloalifático, aromático o heteroaromático opcionalmente sustituido;Ar es un grupo aromático o heteroaromático opcionalmente sustituido; y los sustituyentes restantes fueron definidos en la especificación.Los compuestos son inhibidores selectivos y potentes de la quinasa p38 y son útiles en la profilaxis y el tratamiento de los trastornos inmunitarios o inflamatorios.
-
公开(公告)号：IS7652A
公开(公告)日：2005-01-18
申请号：IS7652
申请日：2005-01-18
Applicant: CELLTECH R&D LTD
IPC: A61K31/4743 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/02 , A61P7/04 , A61P7/06 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P31/16 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07D495/04 , A61K31/44
-
公开(公告)号：AU2004249498A1
公开(公告)日：2004-12-29
申请号：AU2004249498
申请日：2004-06-18
Applicant: CELLTECH R&D LTD
IPC: C07D495/04 , A61K31/4365 , A61P19/02 , A61P29/00 , A61P37/02 , C07D221/00
Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-3-yl, pyrrolidin-3-ylamino or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
-
-
-
-
-
-
-
-
-
Search Results
47
records
(took 0.024 seconds)
